Trials / Completed
CompletedNCT00363727
Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's
A Two Year Phase IIIb Randomised, Multicenter, Double-blind, SINEMET Controlled, Parallel Group, Flexible Dose Study, to Assess the Effectiveness of Controlled Release Ropinirole add-on Therapy to L-dopa at Increasing the Time to Onset of Dyskinesia in Parkinson's Disease Subjects.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 209 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates how effective a new formulation of a marketed drug is in increasing the time to onset of dyskinesia (abnormal twisting, writhing movements) in patients with Parkinson's Disease who have been taking levodopa for less than 2 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ropinirole controlled-release (REQUIP CR) for RLS |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2006-01-01
- Completion
- 2006-01-01
- First posted
- 2006-08-15
- Last updated
- 2017-01-18
Locations
69 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00363727. Inclusion in this directory is not an endorsement.